Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04735471 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ADI-001 in B Cell Malignancies
A Phase 1 study, sponsored by Adicet Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04735471 is a Phase 1 study that was terminated before completion, run by Adicet Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT04735471, a Phase 1 study, was terminated before completion, sponsored by Adicet Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC ADI-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2025-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04735471
The ClinicalTrials.gov registry entry for NCT04735471 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adicet Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04735471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04735471 about?
NCT04735471 is a clinical study titled "A Phase 1 Study of ADI-001 in B Cell Malignancies". This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
What is the current status of trial NCT04735471?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-03-04. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT04735471?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ADI-001 (GENETIC).
Who is sponsoring clinical trial NCT04735471?
This trial is sponsored by Adicet Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.